Shares of ImmuPharma plc (LON:IMM – Get Free Report) shot up 16.2% on Thursday . The stock traded as high as GBX 4.30 and last traded at GBX 4.30. 1,065,174 shares traded hands during trading, a decline of 61% from the average session volume of 2,734,189 shares. The stock had previously closed at GBX 3.70.
ImmuPharma Stock Performance
The stock has a market cap of £26.83 million, a price-to-earnings ratio of -11.62 and a beta of 3.02. The business’s 50 day moving average is GBX 4.21 and its 200-day moving average is GBX 5.46.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
